Outset Medical, Inc. (NASDAQ:OM) Stock Has Consensus Price Target of $10.00 According to Analysts

Shares of Outset Medical, Inc. (NASDAQ:OM) have earned a consensus rating of “Hold” from the five brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $10.00.

Several analysts have recently commented on the company. Wall Street Zen upgraded Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings lowered Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st.

Institutional Investors Weigh In On Outset Medical

Several hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd acquired a new position in shares of Outset Medical during the first quarter worth approximately $65,000. Squarepoint Ops LLC acquired a new stake in Outset Medical in the 2nd quarter valued at $98,000. Bank of New York Mellon Corp acquired a new stake in Outset Medical in the 2nd quarter valued at $121,000. Sei Investments Co. increased its stake in Outset Medical by 15.5% during the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock valued at $136,000 after purchasing an additional 4,738 shares in the last quarter. Finally, Aristides Capital LLC bought a new stake in Outset Medical during the 4th quarter valued at $177,000.

Outset Medical Price Performance

Outset Medical stock opened at $3.96 on Friday. The company has a market capitalization of $74.45 million, a PE ratio of -0.97 and a beta of 1.99. Outset Medical has a 12-month low of $2.84 and a 12-month high of $16.16. The firm’s fifty day moving average is $3.94 and its 200 day moving average is $4.17. The company has a quick ratio of 4.11, a current ratio of 5.19 and a debt-to-equity ratio of 1.03.

Outset Medical (NASDAQ:OM) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%.The company had revenue of $31.64 million during the quarter, compared to analyst estimates of $28.97 million. As a group, sell-side analysts predict that Outset Medical will post -3.81 EPS for the current fiscal year.

About Outset Medical

Outset Medical, Inc is a medical technology company focused on simplifying hemodialysis for patients and healthcare providers. The company’s principal product is the Tablo Hemodialysis System, an integrated dialysis platform designed to combine water purification, dialysate production, treatment monitoring and data connectivity in a single device.

Tablo is intended for use in hospitals, outpatient clinics and other care settings, and has also been cleared for home hemodialysis in the United States.